

RNAi

Technologies, Companies and Markets

By

Prof. K. K. Jain
MD, FRACS, FFPM
Jain PharmaBiotech
Basel, Switzerland

November 2021

A Jain PharmaBiotech Report

AUTHOR'S BIOGRAPHY

Professor K. K. Jain is a neurologist/neurosurgeon with specialist qualifications including Fellowships of the Royal Colleges of Surgeons in Australia and Canada. He has trained, practiced, and held academic positions in several countries including Switzerland, India, Iran, Germany Canada, and USA. After retirement from neurosurgery, Prof. Jain remains a consultant in neurology. He is also working in the biotechnology/biopharmaceuticals industry and is a Fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians of UK. Currently, he is the CEO of Jain PharmaBiotech.

Prof. Jain's 492 publications include 35 books (6 as editor+ 29 as author) and 50 special reports, which have covered important areas in biotechnology, gene therapy and biopharmaceuticals, biomarkers: proteomics, molecular diagnostics, nanobiotechnology, and personalized medicine. Contributions to MedLink, an accredited continuing education program for neurologists, include 172 articles out of a total of 1250 articles by 450 authors. These articles are updated on a yearly basis. Prof. Jain's earlier books were the first in the areas covered: "Handbook of Laser Neurosurgery" (Charles C. Thomas, Springfield, Ill, 1983) and "Textbook of Hyperbaric Medicine" (1st ed in 1990 and 6th ed by Springer, 2017). His "Textbook of Gene Therapy" was translated into Chinese in 2000. Recent books include "Handbook of Nanomedicine" (Springer 2008, Chinese edition by Peking University Press 2011, 3rd ed 2017), "Textbook of Personalized Medicine" (Springer 2009; Japanese ed 2012; 2nd ed Springer 2015, 3rd ed 2021), "Handbook of Biomarkers" (Springer 2010; Chinese ed, Chemical Industry Press 2016, 2nd ed 2017), "Drug-induced Neurological Disorders", 4th ed (Springer 2021), "Handbook of Neuroprotection" (Springer 2011, 2nd ed 2019), "Applications of Biotechnology in Cardiovascular Therapeutics" (Springer 2011), "Applications of Biotechnology in Neurology" (Springer 2013), and "Applications of Biotechnology in Oncology" (Springer 2014). He has also edited 3 editions of "Drug Delivery System" (Springer 2008, 20012 and 2020) and "Applied Neurogenomics" (Springer 2015). Lectures on personalized medicine given at Kazakh National Medical University, Kazakhstan were translated into Russian and published as a book "Essentials of Personalized Medicine" (LITERRA Publishing House, Moscow, 2019). Currently, he is writing "The Handbook of Alzheimer Disease" to be published by Springer in 2022.

November 2021
Copyright © 2021 by

Jain PharmaBiotech
Bläsiring 7
CH-4057 Basel
Switzerland

Tel & Fax: +4161-6924461
Email: info@pharmabiotech.ch
Web site: <http://pharmabiotech.ch/>

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, or otherwise without the prior written permission of the Publisher. This report may not be lent, resold, or otherwise traded in any manner without the consent of the Publisher. While all reasonable steps have been taken to ensure the accuracy of the information presented, the Publisher cannot accept responsibility for inadvertent errors or omissions.

TABLE OF CONTENTS

0. Executive Summary	15
1. Technologies for suppressing gene function	17
Introduction	17
DNA transcription.....	17
RNA	17
<i>Non-coding RNA</i>	<i>17</i>
<i>RNA research and potential applications.....</i>	<i>19</i>
<i>Role of RNA in regulation of the dihydrofolate reductase gene</i>	<i>21</i>
Gene regulation	21
Post-transcriptional regulation of gene expression.....	22
RNA splicing	22
Technologies for gene suppression	23
Antisense oligonucleotides	24
Phosphorodiamidate morpholino oligomers.....	24
Transcription factor decoys	24
Aptamers.....	25
Ribozymes	25
Aptazymes	26
RNA aptamers vs allosteric ribozymes	26
Peptide nucleic acid.....	26
PNA-DNA chimeras.....	27
Locked nucleic acid	27
Long noncoding RNAs.....	27
Gene silencing	28
Post-transcriptional gene silencing	28
Small noncoding RNAs.....	29
TargeTron™ technology for gene knockout	30
Definitions and terminology of RNAi	30
RNAi mechanisms	31
RNAi oligonucleotides	33
Non-promoter-associated small RNAs.....	33
Piwi-interacting RNAs in germ cell development	34
Relation of RNAi to junk DNA.....	34
RNAi and epigenetic mechanisms	35
RNA editing and RNAi	35
Historical landmarks in the development of RNAi	35
2. RNAi Technologies	37
Introduction	37
Comparison of antisense and RNAi	37
Advantages of antisense over siRNAs	37
Advantages of siRNAs over antisense	38
RNA aptamers vs siRNA	38
RNA Lassos versus siRNA.....	38
Concluding remarks on antisense vs RNAi	39
PMOs vs antisense and siRNAs	39
ssRNAi	39
Antisense vs DNP-ssRNA and DNP-siRNA	39
LNA and RNAi.....	40
LNA for gene suppression.....	40
Comparison of LNA and RNAi.....	41
Use of siLNA to improve siRNA.....	41
RNAi versus small molecules	41
RNAi in vivo	42
Cre-regulated RNAi in vivo	42
RNAi kits.....	42
ShortCut™ RNAi Kit.....	42
HiScribe™ RNAi Transcription Kit	43
pSUPER RNAi system.....	43
Si2 Silencing Duplex.....	44
Techniques for measuring RNAi-induced gene silencing	44
Application of PCR in RNAi.....	44
<i>Real-time quantitative PCR.....</i>	<i>45</i>
<i>Assessment of the silencing effect of siRNA by RT-PCR</i>	<i>45</i>
<i>Fluorescence resonance energy transfer probe for RNA interactions</i>	<i>46</i>
Bioinformatics tools for design of siRNAs	46

Random siRNA design.....	46
Rational siRNA design.....	46
<i>The concept of pooling siRNAs</i>	47
<i>Criteria for rational siRNA design</i>	48
<i>BLOCK-iT RNAi Designer</i>	48
<i>QIAGEN's 2-for-Silencing siRNA Duplexes</i>	48
<i>Designing vector-based siRNA</i>	49
<i>iRNAChek for designing siRNA</i>	49
<i>TROD: T7 RNAi Oligo Designer</i>	49
<i>siDirect: siRNA design software</i>	50
Prediction of efficacy of siRNAs	50
<i>Algorithms for prediction of siRNA efficacy</i>	50
<i>siRNA databases</i>	50
Production of siRNAs	50
Chemical synthesis of short oligonucleotides	51
In vitro transcription	51
Generation of siRNAs in vivo	52
UsiRNAs.....	52
siRNA:DNA hybrid molecules	52
Chemical modifications of siRNAs	53
<i>Sugar modifications of siRNA</i>	53
<i>Phosphate linkage modifications of siRNA</i>	53
<i>Modifications to the siRNA overhangs</i>	54
<i>Modifications to the duplex architecture</i>	54
<i>Applications of chemical modification of siRNAs</i>	54
Synthetic RNAs vs siRNAs	55
Specificity of siRNAs	55
Asymmetric interfering RNA	56
Genome-wide data sets for the production of esiRNAs	56
ddRNAi for inducing RNAi	56
ddRNAi technology	56
.....	57
Advantages of ddRNAi over siRNA	57
Short hairpin RNAs	58
siRNA versus shRNA.....	58
Circular interfering RNA	59
Expressed interfering RNA.....	60
RNA-induced transcriptional silencing complex	60
Inhibition of gene expression by antigene RNA	61
RNAi vs mRNA modulation by small molecular weight compounds	61
saRNA for transcriptional activation	62
Synthetic nucleic acid drugs for selective tissue targeting	62
 3. MicroRNA.....	 65
Introduction	65
Circular RNA and miRNA	67
miRNA and RISC	67
Role of the microprocessor complex in miRNA.....	68
miRNAs compared to siRNAs.....	69
miRNA and stem cells	69
Influence of miRNA on stem cell formation and maintenance	69
Role of miRNAs in gene regulation during stem cell differentiation.....	70
miRNA databases.....	71
Sanger miRBase miRNA sequence database	71
Mapping miRNA genes.....	71
A database of ultraconserved sequences and miRNA function	72
A database for miRNA deregulation in human disease.....	72
An database of miRNA-target interactions	72
Role of miRNA in gene regulation	73
Control of gene expression by miRNA	73
<i>miRNA-mediated translational repression involving Piwi</i>	74
<i>Transcriptional regulators of ESCs control of miRNA gene expression</i>	74
Mechanism of miRNAs-induced silencing of gene expression.....	74
miRNA diagnostics.....	75
Biochemical approach to identification of miRNA	75
Computational approaches for the identification of miRNAs	75
LNA probes for exploring miRNA	75
miR-TRAP to identify miRNA targets in vivo	76
Microarrays for analysis of miRNA gene expression	76
<i>Microarrays vs quantitative PCR for measuring miRNAs</i>	77
miRNAs as biomarkers of hepatotoxicity	77

Modification of in situ hybridization for detection of miRNAs	78
Nuclease Protection Assay to measure miRNA expression.....	78
Real-time PCR for expression profiling of miRNAs.....	78
Significance of miRNAs in diagnostics	79
Targeting of miRNAs with antisense oligonucleotides	79
Silencing miRNAs by antagomirs.....	79
New tools for miRNA silencing	80
Use of HAPIScreen for identification of aptamers against pre-miRNAs	80
miRNA-regulated lentiviral vectors.....	80
miRNAs as drug targets	80
miRNAs as targets for antisense drugs.....	81
Challenges facing use of miRNAs as drug targets	81
Target specificity of miRNAs	82
Prediction of miRNA targets.....	82
Role of miRNA in human health and disease	83
Role of miRNAs in regulation of hematopoiesis.....	83
Role of miRNA depletion in tissue regeneration	84
Role of miRNA in regulation of aging	84
Role of miRNA in inflammation	84
Role of miRNAs in regulation of immune system	85
Role of miRNA in diabetes.....	85
Role of miRNA in the cardiovascular system	85
Role of miRNAs in development of the cardiovascular system	86
Role of miRNAs in angiogenesis	86
Role of miRNA in atherosclerosis	86
Role of miRNAs in cardiac hypertrophy and failure	86
Role of miRNA in cardiomyopathy	87
Role of miRNAs in conduction and rhythm disorders of the heart.....	88
Diagnostic and prognostic value of miRNAs in acute coronary syndrome	88
miRNA-based approaches for reduction of hypercholesterolemia	88
miRNA-based approach for restenosis following angioplasty	89
miRNA gene therapy for ischemic heart disease.....	89
miRNAs as therapeutic targets for cardiovascular diseases	90
Concluding remarks and future prospects of miRNA in the cardiovascular system.....	90
Role of miRNAs in diseases of the eye	90
Pathological ocular neovascularization	90
Role of miRNAs in diabetic retinopathy	91
Role of miRNAs in glaucoma.....	91
Role of miRNA in corneal scarring	91
Role of miRNAs in the nervous system.....	92
miRNAs and addiction.....	92
miRNAs in neurodegenerative disorders	93
<i>miRNAs as biomarkers of Alzheimer's disease.....</i>	<i>94</i>
<i>miRNAs in Parkinson disease.....</i>	<i>95</i>
<i>miRNAs in Huntington's disease.....</i>	<i>95</i>
<i>miRNAs in ALS.....</i>	<i>96</i>
<i>miRNAs as biomarkers of prion-induced neurodegeneration.....</i>	<i>97</i>
<i>miRNAs and retinal neurodegenerative disorders</i>	<i>97</i>
<i>miRNA and stroke</i>	<i>97</i>
<i>miRNAs and schizophrenia</i>	<i>98</i>
Role of miRNAs in neuroprotection	98
Role of miRNAs in viral infections	99
Role of miRNA in HSV-1 latency.....	99
miRNA and autoimmune disorders.....	99
miRNA in rheumatoid arthritis	99
miRNA in systemic lupus erythematosus	100
miRNAs in gastrointestinal disorders.....	100
miRNA-based therapies for the irritable bowel syndrome	100
miRNA-based therapies for the inflammatory bowel disease	100
miRNA and skin disorders.....	101
Role of miRNA in inflammatory skin disorders.....	101
Role of miRNA in hypertrophic scarring of the skin	101
Role of miRNAs in cancer	102
miRNAs linked to the initiation and progression of cancer.....	102
Oncomirs	102
Linking miRNA sequences to cancer using RNA samples.....	103
Role of miRNAs in viral oncogenesis	104
miRNA genes in cancer	104
miRNAs interaction with p53	105
miRNAs, embryonic stem cells and cancer.....	105
miRNAs and cancer metastases	105

Role of miRNAs in cancer diagnosis	106
<i>Cancer miRNA signature</i>	106
<i>miRNA biomarkers in cancer</i>	107
<i>Diagnostic value of miRNA in cancer</i>	107
<i>Prognostic value of miRNA in cancer</i>	107
miRNA-based cancer therapeutics	108
<i>Antisense oligonucleotides targeted to miRNA</i>	108
<i>Role of miRNAs in adoptive immunotherapy of cancer</i>	108
<i>Restoration of tumor suppressor miRNAs to inhibit cancer</i>	109
<i>Delivery strategies for miRNA modulators in cancer</i>	109
Role of miRNAs in various cancers	110
<i>miRNA and brain tumors</i>	110
<i>miRNAs and CNS tumors in children</i>	113
<i>miRNAs and pituitary tumors</i>	113
<i>miRNA and breast cancer</i>	113
<i>miRNA and colorectal cancer</i>	114
<i>miRNA and gastrointestinal cancer</i>	115
<i>miRNA and leukemia</i>	115
<i>miRNA and lymphomas</i>	116
<i>miRNA and hepatocellular carcinoma</i>	117
<i>miRNA and lung cancer</i>	117
<i>miRNA and nasopharyngeal carcinoma</i>	119
<i>miRNA and ovarian cancer</i>	119
<i>miRNA and pancreatic cancer</i>	120
<i>miRNA and prostatic cancer</i>	121
<i>miRNA and thyroid cancer</i>	121
Companies involved in miRNA	121
Status of therapeutic development of miRNAs	123
Concluding remarks and future of miRNA therapeutics	124

4. Methods of delivery in RNAi **127**

Introduction	127
Methods of delivery of oligonucleotides	127
Oral and rectal administration	128
Pulmonary administration	128
Targeted delivery to the CNS	129
<i>High flow microinfusion into the brain parenchyma</i>	129
Intracellular guidance by special techniques	129
Biochemical microinjection	130
Liposomes-mediated oligonucleotide delivery	130
Polyethylenimine-mediated oligonucleotide delivery	130
Delivery of TF Decoys	130
Biodegradable microparticles	131
<i>Microparticles</i>	131
<i>Nanoparticles</i>	131
Self-delivering rxRNA	132
siRNA delivery technologies	132
Local delivery of siRNA	133
In vivo delivery of siRNAs by synthetic vectors	133
Intracellular delivery of siRNAs	133
<i>Delivery of siRNAs with aptamer-siRNA chimeras</i>	134
<i>MPG-based delivery of siRNA</i>	135
<i>Protamine-antibody fusion proteins for delivery of siRNA to cells</i>	135
<i>Protein transduction domains</i>	135
<i>Phosphorothioate stimulated cellular delivery of siRNA</i>	136
Targeted delivery of siRNAs by lipid-based technologies	136
<i>Delivery of siRNA-lipoplexes</i>	136
<i>Lipidoids for delivery of siRNAs</i>	136
<i>Lipid-based Unlocked Nucleomonomer Agent</i>	137
<i>NeoLipid™ technology</i>	137
<i>siFECTamine™</i>	138
<i>Systemic in vivo delivery of lipophilic siRNAs</i>	138
<i>Challenges and future prospects of lipid-based siRNA delivery</i>	138
Electroporation	138
<i>Nucleofactor technology</i>	139
<i>Visualization of electrotransfer of siRNA at single cell level</i>	139
Intravascular delivery of siRNA	140
27mer siRNA duplexes for improved delivery and potency	140
TransIT-TKO®	141
DNA-based plasmids for delivery of siRNA	141
<i>Convergent transcription</i>	142

PCR cassettes expressing siRNAs	142
Genetically engineered bacteria for delivery of shRNA.....	142
Viral vectors for delivery of siRNA	143
<i>Adenoviral vectors</i>	143
<i>Adeno-associated virus vectors for shRNA expression</i>	143
<i>Baculovirus vector</i>	143
<i>Lentiviral vectors</i>	144
<i>Retroviral delivery of siRNA</i>	145
Transkingdom RNAi delivery by genetically engineered bacteria.....	145
Delivery of siRNA without a vector	145
Cell-penetrating peptides for delivery of siRNAs	146
Role of nanobiotechnology in siRNA delivery.....	146
<i>Chitosan-coated nanoparticles for siRNA delivery</i>	146
<i>Cyclodextrin nanoparticles</i>	147
<i>Delivery of gold nanorod-siRNA nanoplex to dopaminergic neurons</i>	147
<i>Lipidic aminoglycoside as siRNA nanocarrier</i>	147
<i>Lipid nanoparticles-mediated siRNA delivery</i>	147
<i>Nanoparticles for intracellular delivery of siRNA</i>	148
<i>Nanosize liposomes for delivery of siRNA</i>	148
<i>PAMAM dendrimers for siRNA delivery</i>	149
<i>PEG-PCL-DEX polymersome-protamine vector</i>	149
<i>Polyethylenimine nanoparticles for siRNA delivery</i>	149
<i>Polycation-based nanoparticles for siRNA delivery</i>	150
<i>Quantum dots to monitor siRNA delivery</i>	150
<i>siRNA-nanoparticle conjugates for improving stability in serum</i>	151
<i>Systemic delivery of siRNAi by lipid nanoparticles</i>	151
<i>Topical delivery of siRNA-nanoparticle conjugates</i>	152
Targeted delivery of siRNAs to specific organs	152
<i>siRNA delivery to the CNS</i>	152
<i>siRNA delivery to the liver</i>	153
<i>siRNA delivery to the lungs</i>	153
Control of RNAi and siRNA levels	154
siRNA pharmacokinetics in mammalian cells	154
Mathematical modeling for determining the dosing schedule of siRNA.....	154
Assessing siRNA pharmacodynamics in animal models.....	155
Research on siRNA delivery funded by the NIH.....	155
Companies involved in delivery technologies for siRNA	156
5. RNAi in Research	159
Introduction	159
Basic RNAi research	159
<i>Antiviral role of RNAi in animal cells</i>	159
<i>Combination of siRNA with green fluorescent protein</i>	159
<i>Detection of cancer mutations</i>	160
<i>Genes and lifespan</i>	160
<i>Inducible and reversible RNAi</i>	160
<i>Loss-of-function genetic screens</i>	160
<i>Nanoparticles mimic RNAi</i>	161
<i>Profiling small RNAs</i>	161
<i>RNAi for research in neuroscience</i>	161
<i>RNAi and environmental research</i>	162
<i>Small nucleolar RNAs</i>	162
<i>Study of signaling pathways</i>	162
<i>Transgenic RNAi</i>	163
<i>Use of RNAi to study insulin action</i>	163
Applied RNAi research	163
RNAi for gene expression studies	163
Microarrays for measuring gene expression in RNAi.....	164
RNAi for functional genomic analysis	164
<i>RNAi studies on C. elegans</i>	164
<i>RNAi studies on Drosophila</i>	165
<i>RNAi in planaria</i>	166
RNAi for regenerative medicine.....	166
Testing the specificity of RNAi.....	167
Tissue-specific RNAi	167
siRNA-mediated gene silencing	167
RNAi libraries	167
<i>Enzymatic production of RNAi library</i>	168
<i>Next-generation libraries for RNAi-based genome-wide screens</i>	168
<i>pDual library using plasmid vector</i>	168
<i>pHippy plasmid vector library</i>	169

<i>siRNA libraries using pRetroSuper vector</i>	169
<i>siRNA produced by enzymatic engineering of DNA</i>	169
<i>shRNA libraries</i>	169
RNAi and alternative splicing	170
RNAi in animal development.....	171
<i>RNAi for creating transgenic animals</i>	171
<i>RNAi for creating models of neurological disorders</i>	172
Research support for RNAi in US	172
RNAi for toxicogenomics	172
Role of RNAi in the US biodefense research	173
The RNAi Consortium	173
Research support for RNAi in Europe	174
European Union for RNA Interference Technology	174
Research support of RNAi.....	174
Role of RNAi in MitoCheck project	174
RNAi Global Initiative	175
SIROCCO project	175
6. RNAi in drug discovery	177
Basis of RNAi for drug discovery	177
RIP-Chip for study of RNA-protein interactions.....	177
RNAi for identification of genes as therapeutic targets	178
Role of siRNAs in drug target identification	178
<i>Use of a genome-wide, siRNA library for drug discovery</i>	178
RNAi as a tool for assay development	179
Targeting human kinases with an siRNA library	179
Challenges of drug discovery with RNAi	179
Express Track SM siRNA Drug Discovery Program.....	180
Genome-wide siRNA screens in mammalian cells	180
<i>PhenomicIDTM</i>	181
Natural antisense and ncRNA as drug targets	181
RNAi for target validation.....	181
<i>Delivering siRNA for target validation in vivo</i>	182
<i>Validation of oncology targets discovered through RNAi screens</i>	183
<i>Selection of siRNA versus shRNA for target validation</i>	183
Off-target effects of siRNA-mediated gene silencing	184
<i>Bioinformatic approach to off-target effects</i>	184
<i>siPools for eliminating off-target effects of siRNAs</i>	185
<i>Unlocked Nucleomonomer Agent</i>	185
<i>Managing off-target effects of vector-encoded shRNAs</i>	185
Application of RNAi to the druggable genome	186
Application of siRNA during preclinical drug development	186
siRNAs vs small molecules as drugs.....	187
siRNAs vs antisense drugs.....	187
Chemical modifications for improving siRNA drugs	187
RNAi technology in plants for drug discovery and development	188
<i>Application of RNAi to poppy plant as source of new drugs</i>	188
7. Therapeutic applications of RNAi	189
Introduction	189
Potential of RNAi-based therapies	190
In vitro applications of siRNA	190
In vivo applications of RNAi	191
RNAi and cell therapy	191
Gene inactivation to study hESCs.....	192
RNAi and stem cells	192
<i>RNAi for study of ESCs</i>	193
<i>RNAi and iPSCs</i>	193
Cell therapy for immune disorders	193
RNAi gene therapy	193
Drug-inducible systems for control of gene expression.....	194
Potential side effects of RNAi gene therapy.....	194
Systemic delivery of siRNAs	195
In vivo RNAi therapeutic efficacy in animal models of human diseases.....	195
Role of RNAi in regenerative medicine	196
Virus infections	197
RNAi screens of viral genomes.....	197
RNAi approaches to viral infections.....	197
Delivery of siRNAs in viral infections.....	198
Viral vectors for RNAi-based antiviral therapy	199
Promise and pitfalls of RNAi gene therapy	199

RNAi applications in HIV	199
<i>A multiple shRNA approach for silencing of HIV-1</i>	200
<i>Anti-HIV shRNA for AIDS lymphoma</i>	200
<i>Aptamer-mediated delivery of anti-HIV siRNAs</i>	200
<i>Bispecific siRNA constructs</i>	200
<i>Role of the nef gene during HIV-1 infection and RNAi</i>	201
<i>siRNA-directed inhibition of HIV-1 infection</i>	201
<i>Synergistic effect of snRNA and siRNA</i>	202
<i>Targeting CXCR4 with siRNAs</i>	202
<i>Targeting CCR5 with siRNAs</i>	202
<i>Concluding remarks on RNAi approach to HIV/AIDS</i>	203
Influenza	203
<i>Inhibition of influenza virus by siRNAs</i>	204
<i>Delivery of siRNA in influenza</i>	205
<i>Challenges and future prospects of siRNAs for influenza</i>	205
Respiratory syncytial and parainfluenza viruses	206
Coronavirus/severe acute respiratory syndrome	206
Gene editing with for COVID-19 by RNA-targeting CRISPR systems	207
mRNA vaccines for COVID-19	208
Herpes simplex virus 2	209
Hepatitis B	209
Hepatitis C virus	210
Cytomegalovirus	211
Virus causing hemorrhagic fever	211
<i>Dengue fever</i>	212
<i>Antivirals in development</i>	213
<i>Ebola virus</i>	213
<i>Marburg virus</i>	214
siRNA vs antisense oligonucleotides for viral infections	214
siRNA against methicillin-resistant <i>S. aureus</i>	215
RNAi-based rational approach to antimalarial drug discovery	215
Inhibiting the growth of malarial parasite by heme-binding DNA aptamers	215
siRNA-based antimalarial therapeutics	216
RNAi applications in oncology	216
Allele-specific inhibition	217
Drug delivery issues in managing cancer by RNAi approach	217
Inhibition of oncogenes	218
Modification of alternative splicing in cancer	219
Onconase	219
Overcoming drug resistance in cancer	220
<i>Targeting fusion proteins in cancer</i>	221
<i>Increasing chemosensitivity by RNAi</i>	221
RNAi approach to study TRAIL	221
RNAi-based logic circuit for identification of specific cancer cells	221
shRNA-based autologous cancer vaccine	222
siRNAs for anticancer drug discovery	222
siRNAs based on huntingtin trinucleotide repeats as anticancer reagents	223
siRNAs for inducing cancer immunity	223
siRNAs for inhibition of angiogenesis	224
siRNA targeting the R2 subunit of ribonucleotide reductase	224
siRNA for cancer chemoprevention	224
siHybrids vs siRNAs as anticancer agents	225
Nanobiotechnology-based delivery of siRNAs	225
<i>Lipid nanoparticle-based delivery of anticancer siRNAs</i>	225
<i>Minicells for targeted delivery of nanoscale anticancer therapeutics</i>	226
<i>Nanoimmunoliposome-based system for targeted delivery of siRNA</i>	226
<i>PEG-nanoparticles for delivery of siRNA to target fusion genes</i>	227
<i>Polymer nanoparticles for targeted delivery of anticancer siRNA</i>	227
<i>RNA nanotechnology for delivery of cancer therapeutics</i>	227
<i>siRNA delivery in combination with nanochemotherapy</i>	228
<i>Targeted delivery of a nanoparticle-siRNA complex in cancer patients</i>	228
Lipophilic siRNA for targeted delivery to solid tumors	229
RNAi-based treatment of various cancer types	229
<i>RNAi-based therapy of glioblastoma multiforme</i>	229
<i>RNAi in breast cancer</i>	231
<i>RNAi for enhancing hyperthermia/chemotherapy in cervical cancer</i>	232
<i>RNAi and colorectal cancer</i>	232
<i>RNAi and Ewing's sarcoma</i>	232
<i>RNAi and leukemias</i>	233
<i>RNAi and lung cancer</i>	233
<i>RNAi and melanoma</i>	234

<i>RNAi and pancreatic cancer</i>	234
<i>RNAi and prostate cancer</i>	235
Genetic disorders	235
Acute intermittent porphyria	236
Hereditary transthyretin-mediated amyloidosis	236
Primary hyperoxaluria type 1	237
RNAi for skin disorders	237
Experimental studies for RNAi applications in skin disorders	237
Clinical applications of RNAi in skin disorders	238
Pachyonychia congenita	238
Neurological disorders	238
RNAi for neurodegenerative disorders	239
<i>RNAi for limiting protein aggregation in neurodegenerative diseases</i>	239
<i>Alzheimer's disease</i>	240
<i>Parkinson's disease</i>	241
<i>Amyotrophic lateral sclerosis</i>	242
<i>Prion diseases</i>	242
Polyglutamine-induced neurodegeneration	243
<i>Fragile X syndrome and RNAi</i>	243
<i>RNAi-based therapy for Huntington's disease</i>	244
Combination of RNAi and gene therapy to prevent neurodegenerative disease	245
Role of RNAi in pain therapy	246
Role of RNAi in repair of spinal cord injury	246
Role of RNAi in treatment of multiple sclerosis	247
siRNA for Duchenne muscular dystrophy	247
siRNA for dystonia	247
RNAi in ophthalmology	247
Age related macular degeneration	248
<i>Current treatment of AMD</i>	248
<i>RNAi-based treatments for AMD</i>	249
Diabetic retinopathy	250
Retinitis pigmentosa	251
RNAi and metabolic disorders	251
RNAi and obesity	251
<i>Genes and regulation of body fat</i>	251
RNAi and diabetes	251
<i>Regulation of insulin secretion by a miRNA</i>	252
<i>RNAi for study of genes in animal models of diabetes</i>	252
<i>RNAi for drug discovery in diabetes</i>	252
<i>RNAi for treating liver dysfunction in diabetes</i>	253
<i>siRNAs for study of glucose transporter</i>	253
<i>siRNAs for targeting adipose inflammation in diabetes and obesity</i>	254
RNAi in hematology	254
Stem cell-based gene therapy and RNAi for sickle cell disease	254
Targeting of antithrombin in hemophilia with RNAi	255
RNAi and disorders of the immune system	256
siRNA applications in immunology	256
Use of RNAi in transplantation	257
RNAi for cardiovascular disorders	257
RNAi for atherosclerosis	257
RNAi for hypercholesterolemia	258
siRNAs targeting PCSK9	258
siRNA targeting NADPH oxidase in cardiovascular diseases	259
Role of lncRNA in cardiovascular disorders	260
siRNA for study and treatment of ischemia-reperfusion injury	260
RNAi in respiratory disorders	260
siRNA for cystic fibrosis	260
siRNA for asthma	261
RNAi for musculoskeletal disorders	261
RNAi for rheumatoid arthritis	261
RNAi for bone disorders	263
<i>RNAi for treatment of osteoporosis</i>	263
RNAi for miscellaneous disorders	263
<i>RNAi for transthyretin amyloidosis</i>	263
<i>Antisense for transthyretin amyloidosis</i>	264
Clinical trials of RNAi-based therapies	264
Improving efficacy of siRNAs for clinical trials by improved delivery	265
Role of RNAi in development of personalized medicine	265
Future of RNAi	266
Challenges for the development of RNAi-based therapeutics	266

8. Safety, regulatory and patent issues	269
Introduction	269
Limitations and drawbacks of RNAi	269
Adverse effects of RNAi	269
Effect of siRNAs on interferon response	270
Detection of interferon response	270
Prevention of the interferon response in RNAi	271
Overcoming the innate immune response to siRNAs	271
Toxicity associated with RNAi	272
Selection of siRNAs to improve specificity and efficacy.....	272
Regulatory issues relevant to RNAi.....	272
RNAi patents.....	273
Companies with strong patent position	273
<i>Alnylam</i>	273
<i>Benitec</i>	276
<i>Intradigm</i>	276
<i>Quark Pharmaceuticals</i>	276
<i>Sirna Therapeutics</i>	277
9. Markets for RNAi Technologies	279
Introduction	279
Current and future market potential for RNAi technologies	279
RNAi reagents	280
siRNA markets.....	280
miRNA markets	280
RNAi-based drug discovery and target validation	280
RNAi-based therapeutics.....	280
RNAi market potential according to therapeutic areas.....	281
Market for viral infections	281
Market for cancer.....	282
Market for age related macular degeneration.....	282
Unmet needs in RNAi	282
Strategies for marketing RNAi	283
Choosing optimal indications	283
Strategies according to the trends in healthcare in the next decade	284
Concluding remarks	285
10. Companies involved in RNAi Technologies	287
Introduction	287
Top players in RNAi.....	291
Profiles of companies.....	291
Collaborations.....	487
11. References.....	495

Tables

Table 1-1: Various types of RNA	20
Table 1-2: Classification of small RNA molecules.....	30
Table 1-3: Mechanisms of small RNAs involved in gene silencing	32
Table 1-4: Historical landmarks in the evolution of RNAi	36
Table 2-1: RNAi versus small molecules.....	42
Table 2-2: Providers of software for siRNA design	47
Table 2-3: Methods for the production of siRNAs	51
Table 2-4: Advantages and limitations of methods of shRNA-derived siRNA knockdown	59
Table 2-5: Comparison of eiRNA with siRNA	60
Table 3-1: Methods for miRNA target prediction	82
Table 3-2: miRNA expression in neurodegenerative diseases.....	94
Table 3-3: Dysregulation of miRNA expression in epithelial cancers.....	103
Table 3-4: Delivery strategies for miRNA inhibition therapies in cancer.....	109
Table 3-5: Delivery strategies for miRNA replacement to inhibit cancer growth.....	109
Table 3-6: MiRNAs and key molecules in signaling pathways in glioblastoma	110
Table 3-7: Companies involved in miRNA diagnostics and therapeutics	121
Table 3-8: Status of therapeutic development of miRNAs.....	123
Table 4-1: Methods of delivery of oligonucleotides	127
Table 4-2: Methods of delivery of siRNA	132
Table 4-3: Companies developing siRNA delivery technologies.....	156
Table 5-1: RNAi libraries.....	167
Table 6-1: Delivery of siRNAs in vivo for target validation	182

Table 6-2: Selection of siRNA versus shRNA for target validation	183
Table 7-1: RNAi-based therapeutic approaches.....	190
Table 7-2: In vivo RNAi therapeutic efficacy in animal models of human diseases	195
Table 7-3: Inhibition of viral replication by RNAi	198
Table 7-4: Cancer-associated genes that can be targeted by RNAi	218
Table 7-5: Neurological disorders that have been studied by using RNAi.....	239
Table 7-6: Clinical trials of RNAi-based therapeutics.....	264
Table 9-1: RNAi markets according to technologies and reagents 2020-2030	279
Table 9-2: Markets for RNAi therapy for selected diseases: years 2020-2030	281
Table 10-1: RNAi reagent, technology and service companies	287
Table 10-2: Pharmaceutical companies using RNAi for drug discovery and development	288
Table 10-3: Biotechnology companies using RNAi for drug discovery and development.....	289
Table 10-4: Companies developing RNAi-based therapeutic products	290
Table 10-5: Ten top players in RNAi	291
Table 10-6: Proprietary reagents of ImuThes	369
Table 10-7: Product pipeline of Silence Therapeutics	456
Table 10-8: Collaborations in RNAi technologies	487

Figures

Figure 1-1: Relationship of DNA, RNA and protein in the cell	22
Figure 1-2: tsRNAs in a model of hepatocellular carcinoma	29
Figure 1-3: Schematic of suppression of gene expression by RNAi	31
Figure 1-4: Relation of RNAi to epigenetic mechanisms	35
Figure 2-1: Overview of ShortCut RNAi Kit.....	43
Figure 2-2: Gene silencing by RNAi induced with ddRNAi	57
Figure 2-3: saRNA for targeted gene activation	62
Figure 3-1: A schematic miRNA pathway with points of action of miRNA tools	65
Figure 3-2: Molecular mechanisms of miRNA generation.....	66
Figure 3-3: miRNA alternations in neurodegenerative diseases	93
Figure 3-4: Multiple targets of miRNAs	102
Figure 4-1: RNA aptamer-mediated targeted RNAi delivery in cancer therapy.....	134
Figure 7-1: Targeting disease by RNAi.....	189
Figure 7-2: Identification of protein targets in neurodegenerative disorders	240
Figure 7-3: Mechanism of action of inclisiran	259
Figure 7-4: Role of RNAi in personalized medicine.....	266
Figure 8-1: Problems with use of synthetic siRNAs and measures to prevent them.....	270
Figure 9-1: Unmet needs in RNAi technologies	283